Payment overview · 2025
General Payments
$46,509.47
263 reported records · 15 companies
Healthcare provider profile · identity verified
Alexandra Smith
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · TYLER, TX · NPI 1871948992
Verified facts
What the public records show
CMS Open Payments records show Alexandra Smith received $46,509.47 in general payments during 2025 across 263 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 62.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Asimtufii, Abilify Maintena, Fanapt, Ingrezza, Invega Sustenna, Rexulti, Uzedy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Vraylar by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Invega Trinza by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 488 records involving 397 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Invega Sustenna by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 23 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Invega Trinza by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY ASIMTUFII as an associated drug or biological on 4974 records involving 1745 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abilify Asimtufii by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY ASIMTUFII as an associated drug or biological on 37017 records involving 12446 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abilify Asimtufii by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Uzedy by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29,223.76 | 62.8% | 108 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15,127.54 | 32.5% | 43 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $419.09 | 0.9% | 19 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $403.44 | 0.9% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $276.24 | 0.6% | 14 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $250.94 | 0.5% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $246.34 | 0.5% | 14 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $233.37 | 0.5% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.45 | 0.3% | 11 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $60.00 | 0.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $54.99 | 0.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.99 | 0.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.37 | 0.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.22 | 0.0% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $13.73 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,643.00 | 24 |
| Travel and Lodging | $9,054.43 | 51 |
| Food and Beverage | $5,500.55 | 186 |
| Consulting Fee | $200.00 | 1 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $28,827.60 | 101 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $15,226.87 | 47 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15,056.79 | 38 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $419.09 | 19 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $403.44 | 14 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $284.67 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $276.24 | 14 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $250.94 | 16 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $205.85 | 15 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $205.85 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $147.01 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145.45 | 11 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC | $114.99 | 4 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY ASIMTUFII abilify asimtufii |
2025 | Abilify Asimtufii | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 96 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 109 | exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 130 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
130 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
131 | 21 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 488 supporting records · 397 recipient NPIs · example record 1174147651 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
131 | 21 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 23 supporting records · 23 recipient NPIs · example record 1174152815 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY ASIMTUFII open payments reported associated product |
CMS Open Payments — General Payments 4974 supporting records · 1745 recipient NPIs · example record 1251759998 |
Abilify Asimtufii · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY ASIMTUFII open payments reported associated product |
CMS Open Payments — General Payments 37017 supporting records · 12446 recipient NPIs · example record 1227267748 |
Abilify Asimtufii · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 530 | 84 |
| Trazodone Hcl | Trazodone Hcl | 388 | 76 |
| Buspirone Hcl | Buspirone Hcl | 378 | 62 |
| Aripiprazole | Aripiprazole | 354 | 61 |
| Mirtazapine | Mirtazapine | 308 | 64 |
| Sertraline Hcl | Sertraline Hcl | 308 | 59 |
| Benztropine Mesylate | Benztropine Mesylate | 282 | 53 |
| Lamotrigine | Lamotrigine | 276 | 40 |
| Gabapentin | Gabapentin | 254 | 44 |
| Olanzapine | Olanzapine | 236 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 234 | 49 |
| Divalproex Sodium Er | Divalproex Sodium | 221 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 220 | 33 |
| Clonidine Hcl | Clonidine Hcl | 219 | 38 |
| Bupropion Xl | Bupropion Hcl | 216 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 204 | 33 |
| Risperidone | Risperidone | 197 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 36 |
| Haloperidol | Haloperidol | 180 | 26 |
| Paliperidone Er | Paliperidone | 150 | 21 |
| Prazosin Hcl | Prazosin Hcl | 137 | 29 |
| Invega Sustenna | Paliperidone Palmitate | 131 | 21 |
| Vraylar | Cariprazine Hcl | 130 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 19 |
| Oxcarbazepine | Oxcarbazepine | 114 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 109 | 18 |
| Rexulti | Brexpiprazole | 109 | 25 |
| Abilify Maintena | Aripiprazole | 96 | 16 |
| Lithium Carbonate Er | Lithium Carbonate | 96 | 14 |
| Lurasidone Hcl | Lurasidone Hcl | 95 | 14 |
| Naltrexone Hcl | Naltrexone Hcl | 95 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 17 |
| Clonazepam | Clonazepam | 82 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 69 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 64 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 55 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 51 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | 11 |
| Clozapine | Clozapine | 49 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 48 | 11 |
| Topiramate | Topiramate | 46 | 11 |
| Amantadine | Amantadine Hcl | 43 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 43 | 11 |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 43 | suppressed |
| Ingrezza | Valbenazine Tosylate | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 36 | 12 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 30 | suppressed |
| Abilify Asimtufii | Aripiprazole | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Fanapt | Iloperidone | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Uzedy | Risperidone | 20 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Invega Hafyera | Paliperidone Palmitate | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Perphenazine | Perphenazine | 14 | suppressed |
| Perseris | Risperidone | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46,509.47 · 263 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REXULTI, Secuado, UZEDY, VIVITROL, VRAYLAR, Xelstrym | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Asimtufii play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error